Goldman Sachs’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-29,807
| Closed | -$451K | – | 6211 |
|
|
2024
Q2 | $451K | Buy |
29,807
+15,336
| +106% | +$228K | ﹤0.01% | 4889 |
|
|
2024
Q1 | $214K | Sell |
14,471
-20,726
| -59% | -$291K | ﹤0.01% | 5089 |
|
|
2023
Q4 | $472K | Buy |
35,197
+244
| +0.7% | +$3.08K | ﹤0.01% | 4779 |
|
|
2023
Q3 | $431K | Buy |
34,953
+20,811
| +147% | +$252K | ﹤0.01% | 4714 |
|
|
2023
Q2 | $174K | Sell |
14,142
-20,756
| -59% | -$260K | ﹤0.01% | 5229 |
|
|
2023
Q1 | $429K | Buy |
34,898
+20,756
| +147% | +$244K | ﹤0.01% | 4912 |
|
|
2022
Q4 | $162K | Buy |
+14,142
| New | +$116K | ﹤0.01% | 5371 |
|
|
2022
Q3 | – | Sell |
-14,142
| Closed | -$84K | – | 6866 |
|
|
2022
Q2 | $84K | Buy |
+14,142
| New | +$79.8K | ﹤0.01% | 5914 |
|
|
2019
Q2 | – | Sell |
-33,572
| Closed | -$184K | – | 5537 |
|
|
2019
Q1 | $184K | Sell |
33,572
-103
| -0.3% | -$473 | ﹤0.01% | 4821 |
|
|
2018
Q4 | $102K | Sell |
33,675
-58,706
| -64% | -$204K | ﹤0.01% | 4993 |
|
|
2018
Q3 | $387K | Sell |
92,381
-80,781
| -47% | -$340K | ﹤0.01% | 4560 |
|
|
2018
Q2 | $669K | Buy |
173,162
+136,499
| +372% | +$906K | ﹤0.01% | 4337 |
|
|
2018
Q1 | $232K | Sell |
36,663
-12,497
| -25% | -$103K | ﹤0.01% | 4923 |
|
|
2017
Q4 | $396K | Sell |
49,160
-89,411
| -65% | -$834K | ﹤0.01% | 5005 |
|
|
2017
Q3 | $1.58M | Buy |
138,571
+22,810
| +20% | +$240K | ﹤0.01% | 4171 |
|
|
2017
Q2 | $1.13M | Sell |
115,761
-44,980
| -28% | -$919K | ﹤0.01% | 4349 |
|
|
2017
Q1 | $3.9M | Buy |
160,741
+140,197
| +682% | +$3.51M | ﹤0.01% | 3150 |
|
|
2016
Q4 | $660K | Buy |
20,544
+5,292
| +35% | +$226K | ﹤0.01% | 4819 |
|
|
2016
Q3 | $762K | Buy |
15,252
+1,221
| +9% | +$50.7K | ﹤0.01% | 4656 |
|
|
2016
Q2 | $595K | Buy |
14,031
+6,445
| +85% | +$351K | ﹤0.01% | 4689 |
|
|
2016
Q1 | $499K | Buy |
7,586
+3,911
| +106% | +$204K | ﹤0.01% | 4741 |
|
|
2015
Q4 | $229K | Sell |
3,675
-20,051
| -85% | -$1.41M | ﹤0.01% | 5590 |
|
|
2015
Q3 | $1.59M | Sell |
23,726
-10,208
| -30% | -$833K | ﹤0.01% | 4025 |
|
|
2015
Q2 | $3.3M | Sell |
33,934
-2,215
| -6% | -$211K | ﹤0.01% | 3340 |
|
|
2015
Q1 | $3.38M | Sell |
36,149
-3,004
| -8% | -$256K | ﹤0.01% | 3282 |
|
|
2014
Q4 | $3.48M | Sell |
39,153
-224
| -0.6% | -$16.3K | ﹤0.01% | 3312 |
|
|
2014
Q3 | $2.72M | Sell |
39,377
-44,278
| -53% | -$2.37M | ﹤0.01% | 3628 |
|
|
2014
Q2 | $4.8M | Buy |
83,655
+58,448
| +232% | +$2.97M | ﹤0.01% | 3092 |
|
|
2014
Q1 | $1M | Buy |
25,207
+3,278
| +15% | +$140K | ﹤0.01% | 4674 |
|
|
2013
Q4 | $920K | Buy |
21,929
+1,310
| +6% | +$38K | ﹤0.01% | 4810 |
|
|
2013
Q3 | $615K | Buy |
20,619
+1,019
| +5% | +$35.6K | ﹤0.01% | 5001 |
|
|
2013
Q2 | $1.04M | Buy |
+19,600
| New | +$859K | ﹤0.01% | 4367 |
|
Goldman Sachs's MACK Position: Q3 2024 in Review
Goldman Sachs sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q3 2024, closing a stake of 29,807 shares — an estimated $451K sold.
Goldman Sachs first reported a position in MACK in Q2 2013 and held it in 32 quarters. The position peaked at $4.8M in Q2 2014. 2 funds tracked by Wall St. Rank hold MACK as of Q3 2024.
- Goldman Sachs reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q3 2024 after selling out during the quarter.
- Goldman Sachs sold 29,807 Merrimack Pharmaceuticals, Inc. shares in Q3 2024, an estimated $451K.
- Goldman Sachs first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and held it in 32 quarters.
- Goldman Sachs's Merrimack Pharmaceuticals, Inc. position peaked at $4.8M in Q2 2014.
- 2 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q3 2024.
Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.